NURIX THERAPEUTICS INC's ticker is NRIX and the CUSIP is 67080M103. A total of 69 filers reported holding NURIX THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 1.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $267,601 | -33.1% | 34,046 | -14.9% | 0.00% | – |
| Q2 2023 | $399,730 | +34.7% | 40,013 | +19.7% | 0.00% | – |
| Q1 2023 | $296,858 | +1490.4% | 33,430 | +1866.5% | 0.00% | – |
| Q4 2022 | $18,666 | -45.1% | 1,700 | -35.3% | 0.00% | – |
| Q3 2022 | $34,000 | -10.5% | 2,626 | -11.3% | 0.00% | – |
| Q2 2022 | $38,000 | -74.7% | 2,960 | -72.4% | 0.00% | – |
| Q1 2022 | $150,000 | -75.3% | 10,726 | -48.8% | 0.00% | – |
| Q4 2021 | $607,000 | +38.9% | 20,956 | +44.0% | 0.00% | – |
| Q3 2021 | $437,000 | +4755.6% | 14,554 | +4448.1% | 0.00% | – |
| Q2 2021 | $9,000 | -97.9% | 320 | -97.7% | 0.00% | – |
| Q1 2021 | $430,000 | -72.5% | 13,815 | -70.9% | 0.00% | – |
| Q4 2020 | $1,562,000 | +27.0% | 47,507 | +34.8% | 0.00% | – |
| Q3 2020 | $1,230,000 | – | 35,246 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ponoi II Management, LLC | 561,574 | $16,825,000 | 24.93% |
| Ponoi Management, LLC | 561,573 | $16,825,000 | 14.94% |
| TRV GP III, LLC | 2,422,549 | $72,580,000 | 13.78% |
| Foresite Capital Management IV, LLC | 1,205,798 | $36,126,000 | 5.32% |
| Foresite Capital Management V, LLC | 451,522 | $13,528,000 | 4.20% |
| WestHill Financial Advisors, Inc. | 283,333 | $8,489,000 | 2.62% |
| DAFNA Capital Management LLC | 306,320 | $9,177,000 | 2.44% |
| Bain Capital Life Sciences Investors, LLC | 1,284,314 | $38,478,000 | 2.39% |
| REGENTS OF THE UNIVERSITY OF CALIFORNIA | 571,212 | $17,113,000 | 2.02% |
| Redmile Group, LLC | 3,093,077 | $92,669,000 | 1.62% |